Correspondence 0001214659-25-018126 from Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Dec. 17, 2025 · CIK: 0001643918 · Accession: 0001214659-25-018126
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291598
Letter
Re: Biodexa Pharmaceuticals PLC
December 17, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Sprague Hamill and Alan Campbell
Registration Statement on Form F-1
Registration No. 333-291598
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the "Act"), Maxim Group LLC, as Sole Placement Agent (the "Placement Agent"), hereby joins Biodexa Pharmaceuticals PLC (the "Company") in requesting that the Securities and Exchange Commission take appropriate action to cause the above-referenced registration statement on Form F-1 (the "Registration Statement"), to become effective as of 5:30 p.m., Eastern Time, on December 17, 2025, or as soon thereafter as is practicable, or at such other time as the Company or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, the undersigned advises that copies of the preliminary prospectus are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus prior to the requested effective time of the Registration Statement.
The Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended,.
Very truly yours,
MAXIM GROUP LLC
Show Raw Text
CORRESP 1 filename1.htm December 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Sprague Hamill and Alan Campbell Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-1 Registration No. 333-291598 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the "Act"), Maxim Group LLC, as Sole Placement Agent (the "Placement Agent"), hereby joins Biodexa Pharmaceuticals PLC (the "Company") in requesting that the Securities and Exchange Commission take appropriate action to cause the above-referenced registration statement on Form F-1 (the "Registration Statement"), to become effective as of 5:30 p.m., Eastern Time, on December 17, 2025, or as soon thereafter as is practicable, or at such other time as the Company or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, the undersigned advises that copies of the preliminary prospectus are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus prior to the requested effective time of the Registration Statement. The Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended,. Very truly yours, MAXIM GROUP LLC By: /s/ Ritesh M. Veera Name: Ritesh M. Veera Title: Co-Head of Investment Banking